Trial Profile

Phase I/II Study of Autologous T Cells Engineered Using the Sleeping Beauty System to Express T-Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 31 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TCR T cell therapy (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
Indications Adenocarcinoma; Adenosquamous carcinoma; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms TCR-T Library
Sponsors Alaunos Therapeutics

Most Recent Events

25 May 2024 Planned End Date changed from 1 Mar 2029 to 30 Nov 2024.
25 May 2024 Planned primary completion date changed from 1 Dec 2025 to 30 Nov 2024.
24 Aug 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com